Side effects of drugs annual: a worldwide yearly survey of new data in adverse drug reactions. Ray SD, ed. Waltham, MA: Elsevier, 2017 Nov; 39:269-282
The Side Effects of Drugs Annuals is a series of volumes in which the adverse effects of drugs and adverse reactions to them are surveyed. This review of the January 2016 to December 2016 publications on antiviral drugs includes drugs that are active against cytomegalovirus (cidofovir, letermovir, brincidofovir, foscarnet, ganciclovir and valganciclovir); drugs that are active against herpesviruses (aciclovir, famciclovir and valaciclovir); drugs that are active against hepatitis viruses (adefovir, boceprevir, telaprevir, ribavirin, telbivudine, faldaprevir, sofosbuvir and simeprevir); drugs that are active against HIV, including nucleoside analogue reverse transcriptase inhibitors (didanosine, emtricitabine, lamivudine, stavudine and zidovudine), the nucleotide analogue reverse transcriptase inhibitor tenofovir, nonnucleoside reverse transcriptase inhibitors (efavirenz, etravirine, nevirapine and rilpivirine), protease inhibitors (amprenavir/fosamprenavir, atazanavir, darunavir, lopinavir, ritonavir and saquinavir), the inhibitor of HIV fusion enfuvirtide, the integrase inhibitor dolutegravir and raltegravir, and the chemokine receptor CCR5 antagonist maraviroc; and drugs active against influenza viruses, including the neuraminidase inhibitor oseltamivir and the ion channel inhibitor imiquimod.
Drugs; Viral-diseases; Viral-infections; Preventive-medicine; Infectious-diseases; Infection-control; Treatment;
Author Keywords: Adefovir; Adverse reactions; Amprenavir; Antiretroviral drugs; Atazanavir; Boceprevir; Chemokine receptor CCR5 antagonists; Cidofovir; Cytomegalovirus; Darunavir; Didanosine; Dolutegravir; Efavirenz; Emtricitabine; Enfuvirtide; Etravirine; Famciclovir; Fosamprenavir; Foscarnet; Ganciclovir; Hepatitis viruses; Herpesviruses; HIV; Imiquimod; Indinavir; Influenza viruses; Inhibitors of HIV fusion; Integrase inhibitors; Ion channel inhibitors; Lamivudine; Lopinavir; Maraviroc; Nelfinavir; Neuraminidase inhibitors; Nevirapine; Non-nucleoside reverse transcriptase inhibitors; Nucleoside analogue reverse transcriptase inhibitors; Nucleotide analogue reverse transcriptase inhibitor; Oseltamivir; Protease inhibitors; Raltegravir; Ribavirin; Rilpivirine; Ritonavir; Simeprevir; Sofosbuvir; Stavudine; Telaprevir; Tenofovir; Tipranavir; Valaciclovir; Valganciclovir
Sreekumar Othumpangat, Allergy and Clinical Immunology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1095 Willowdale Road, Morgantown, WV 26505